Moreover, the liposome-encapsulated Tat(48–60) YVEEL showed a long retention of signal primarily in the intestines (Figure 6B), suggesting a promising approach to enhance the bioavailability and therapeutic effect of Tat(48–60) YVEEL on NEC. The gene discussed is TAT; the disease is necrotizing enterocolitis.